Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Wistar Institute patents new antibacterials against Pseudomonas

Feb. 12, 2021

FDA clears IND for phase I/II trial of PhageBank in prosthetic joint infections

Feb. 11, 2021

mNb6-tri, a novel potent trivalent nanobody against SARS-CoV-2

Feb. 11, 2021

NanoViricides reports animal safety data on broad-spectrum anti-coronavirus drug candidate NV-CoV-2

Feb. 11, 2021

FDA grants EUA for etesevimab and bamlanivimab for mild to moderate COVID-19

Feb. 10, 2021

Idorsia Pharmaceuticals discloses new antibacterials

Feb. 10, 2021

Microbiome fungi counter systemic infections

Feb. 10, 2021

Positive interim phase I data presented for COVID-19 vaccine candidate UB-612

Feb. 9, 2021

Ad5-nCoV vaccine meets prespecified primary safety and efficacy criteria for phase III study

Feb. 9, 2021

Phase I trial shows MB-66 to be acceptable and effective in healthy reproductive women

Feb. 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...